Amneal Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 0/6
Amneal Pharmaceuticals does not have a record of paying a dividend.
Key information
0%
Dividend yield
0.2%
Buyback Yield
Total Shareholder Yield | 0.2% |
Future Dividend Yield | 0% |
Dividend Growth | n/a |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Payout ratio | 0% |
Recent dividend and buyback updates
No updates
Recent updates
There's No Escaping Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Muted Revenues
Feb 17Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price
Nov 10Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success
Jul 10Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price
Apr 15Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?
Mar 19Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry
Dec 28Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company
Dec 10Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?
Nov 28Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt
Sep 24Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?
Aug 08Amneal Pharmaceuticals Could Have An Upbeat Q2
Jul 10These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively
Apr 18Amneal Pharmaceuticals: Risk Still Persists
Jan 23Amneal Pharma reaffirms 2022 guidance
Jan 10Amneal joins hands with Orion to commercialize generic products in Europe and more countries
Jan 04Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load
Dec 20Amneal Pharmaceuticals large shareholder TPG cuts stake
Dec 14FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203
Nov 11Amneal Pharmaceuticals Q3 2022 Earnings Preview
Nov 03Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if AMRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMRX's dividend payments have been increasing.
Dividend Yield vs Market
Amneal Pharmaceuticals Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (AMRX) | 0% |
Market Bottom 25% (US) | 1.6% |
Market Top 25% (US) | 4.8% |
Industry Average (Pharmaceuticals) | 2.4% |
Analyst forecast (AMRX) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate AMRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AMRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: AMRX is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AMRX has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/03/14 21:50 |
End of Day Share Price | 2025/03/14 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amneal Pharmaceuticals, Inc. is covered by 20 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Balaji Prasad | Barclays |
Balaji Prasad | Barclays |
Gary Nachman | BMO Capital Markets Equity Research |